Table 4.

Risk for developing second primary stomach cancer by age, sex, latency, and stage among adult 1-y NHL survivors, 17 SEER registry areas, 2000 to 2014

CharacteristicCLL/SLLDLBCLFLMZL
ObsSIR*95% CI*ObsSIR*95% CI*ObsSIR*95% CI*ObsSIR*95% CI*
Age at first primary NHL, y             
 <60 <5 0.43 0.12-1.11 17 1.75† 1.02-2.80 <5 0.23† 0.03-0.83 13 3.83† 2.04-6.56 
 ≥60 35 0.76 0.53-1.06 45 1.44† 1.05-1.93 24 1.03 0.66-1.54 31 2.50† 1.70-3.54 
 Pheterogeneity‡ .26 .51 .01 .22 
Sex             
 Male 30 0.74 0.50-1.05 38 1.37 0.97-1.88 16 0.77 0.44-1.25 27 2.80† 1.84-4.07 
 Female 9 0.62 0.28-1.17 24 1.82† 1.16-2.70 10 0.90 0.43-1.65 17 2.76† 1.61-4.42 
 Pheterogeneity‡ .60 .27 .78 .98 
Latency, y             
 <5 26 0.75 0.49-1.10 35 1.42 0.99-1.98 16 0.88 0.50-1.43 25 2.62† 1.70-3.87 
 ≥5 13 0.63 0.34-1.08 27 1.65† 1.09-2.41 10 0.73 0.35-1.34 19 3.03† 1.82-4.73 
 Pheterogeneity‡ .73 .64 .90 .78 
Stage of first primary NHL§             
 Early 30 0.74 0.50-1.06 30 1.34 0.91-1.92 13 0.88 0.47-1.51 31 3.79† 2.58-5.39 
 Advanced 9 0.60 0.27-1.14 28 1.74† 1.16-2.52 11 0.75 0.38-1.35 10 2.00 0.96-3.68 
 Unknown 0 0 NA <5 1.58 0.43-4.05 <5 0.78 0.09-2.80 <5 1.13 0.23-3.31 
 Pheterogeneity‡ .60 .32 .78 .07 
Initial NHL treatment             
 CT and RT 0 0 NA 14 1.38 0.76-2.32 <5 1.51 0.41-3.88 5 6.64† 2.15-15.48 
 CT, no known RT 6 0.57 0.21-1.23 37 1.53† 1.07-2.10 11 0.75 0.37-1.34 13 3.14† 1.67-5.37 
 RT, no known CT 0 0 NA <5 3.22 0.66-9.41 <5 0.90 0.19-2.63 7 2.26 0.91-4.65 
 No known CT or RT 33 0.75 0.52-1.05 8 1.42 0.61-2.81 8 0.71 0.31-1.40 19 2.43† 1.46-3.79 
 Pheterogeneity‡ .73 .68 .64 .30 
CharacteristicCLL/SLLDLBCLFLMZL
ObsSIR*95% CI*ObsSIR*95% CI*ObsSIR*95% CI*ObsSIR*95% CI*
Age at first primary NHL, y             
 <60 <5 0.43 0.12-1.11 17 1.75† 1.02-2.80 <5 0.23† 0.03-0.83 13 3.83† 2.04-6.56 
 ≥60 35 0.76 0.53-1.06 45 1.44† 1.05-1.93 24 1.03 0.66-1.54 31 2.50† 1.70-3.54 
 Pheterogeneity‡ .26 .51 .01 .22 
Sex             
 Male 30 0.74 0.50-1.05 38 1.37 0.97-1.88 16 0.77 0.44-1.25 27 2.80† 1.84-4.07 
 Female 9 0.62 0.28-1.17 24 1.82† 1.16-2.70 10 0.90 0.43-1.65 17 2.76† 1.61-4.42 
 Pheterogeneity‡ .60 .27 .78 .98 
Latency, y             
 <5 26 0.75 0.49-1.10 35 1.42 0.99-1.98 16 0.88 0.50-1.43 25 2.62† 1.70-3.87 
 ≥5 13 0.63 0.34-1.08 27 1.65† 1.09-2.41 10 0.73 0.35-1.34 19 3.03† 1.82-4.73 
 Pheterogeneity‡ .73 .64 .90 .78 
Stage of first primary NHL§             
 Early 30 0.74 0.50-1.06 30 1.34 0.91-1.92 13 0.88 0.47-1.51 31 3.79† 2.58-5.39 
 Advanced 9 0.60 0.27-1.14 28 1.74† 1.16-2.52 11 0.75 0.38-1.35 10 2.00 0.96-3.68 
 Unknown 0 0 NA <5 1.58 0.43-4.05 <5 0.78 0.09-2.80 <5 1.13 0.23-3.31 
 Pheterogeneity‡ .60 .32 .78 .07 
Initial NHL treatment             
 CT and RT 0 0 NA 14 1.38 0.76-2.32 <5 1.51 0.41-3.88 5 6.64† 2.15-15.48 
 CT, no known RT 6 0.57 0.21-1.23 37 1.53† 1.07-2.10 11 0.75 0.37-1.34 13 3.14† 1.67-5.37 
 RT, no known CT 0 0 NA <5 3.22 0.66-9.41 <5 0.90 0.19-2.63 7 2.26 0.91-4.65 
 No known CT or RT 33 0.75 0.52-1.05 8 1.42 0.61-2.81 8 0.71 0.31-1.40 19 2.43† 1.46-3.79 
 Pheterogeneity‡ .73 .68 .64 .30 
*

SIRs and exact Poisson-based 95% CIs compared number of observed cases with that expected in general population (additional details provided in “Methods”).

†

Indicates 95% CI excludes 1.00, corresponding to 2-sided P < .05.

‡

P values to test differences in SIRs were computed using likelihood ratio test derived from Poisson regression models stratified by age at first primary NHL, sex, and latency, with log of expected numbers of cases included as offset. Exact numbers of cases are not reported for categories with <5 observed cases to maintain patient confidentiality. All statistical tests were 2 sided.

§

Early stage: stages I and II for DLBCL, FL, and MZL and no known initial treatment of CLL; advanced stage: stages III and IV for DLBCL, FL, and MZL and any initial treatment of CLL.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal